Invention Application
- Patent Title: DIAGNOSTIC MIRNAS FOR DIFFERENTIAL DIAGNOSIS OF INCIDENTAL PANCREATIC CYSTIC LESIONS
- Patent Title (中): 诊断性胰腺炎患者的诊断意义
-
Application No.: PCT/US2013/030990Application Date: 2013-03-13
-
Publication No.: WO2014055117A1Publication Date: 2014-04-10
- Inventor: WYLIE, Dennis , SCHWARZBACH, Anna , ANDRUSS, Bernard , ADAI, Alex , LEE, Linda, S. , CONWELL, Darwin, L.
- Applicant: ASURAGEN, INC.
- Applicant Address: 2150 Woodward St., Suite 100 Austin, TX 78744 US
- Assignee: ASURAGEN, INC.
- Current Assignee: ASURAGEN, INC.
- Current Assignee Address: 2150 Woodward St., Suite 100 Austin, TX 78744 US
- Agency: SHISHIMA, Gina, N.
- Priority: US61/709,411 20121004; US61/716,396 20121019
- Main IPC: C12Q1/68
- IPC: C12Q1/68
Abstract:
Embodiments concern methods and compositions for characterizing or evaluating neoplastic pancreatic cells using miRNAs that are measured and used in calculations to determine a risk score for a patient. The pancreatic cells may be characterized as mucinous cystic neoplasm (MCN), serous cystadenoma (SN), pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN) or a subtype thereof. Benign cells may be distinguished from pre-malignant or malignant pancreatic cells.
Information query
